Fundraising FoxVersant Ventures — 2018 Investments
8 investments dated 2018 · listed companies and verified rows first · show all
Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Board seatCarlo Rizzuto· per SEC Form D · $80M raise · filed Apr 2020
Co-investorsAccess BiotechnologyJDRF T1D FundMission BiocapitalRA CapitalSR One Capital ManagementPolaris Partners
AlterG develops anti-gravity treadmill systems using patented Differential Air Pressure technology to enable rehabilitation and athletic training.
HardwareHealthtechMedical DevicesSports TechFremont, US
Ross Jaffe(Director)Charles Remsberg(Executive Officer, Director)Antonio Mora(Director)David Grenewetzki(Director)Kevin Davidge(Executive Officer)Mark McKee(Director)
Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.
HardwareHealthtechMedical DevicesIrvine, US
William H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)
BoardDonald Milder(Director)Kirk Nielsen(Director)inJonathan Root(Director)inBrian Cox(Director)
Co-investorsGilde HealthcareUS Venture PartnersVensana Capital
BiotechSan Diego, US
Jeffrey Stafford, Ph.D.(Executive Officer, Director)James Veal, Ph.D.(Executive Officer)Ariel Feldstein, M.D.(Director)
BoardBradley Bolzon, Ph.D.(Director)Thomas Woiwode, Ph.D.(Director)
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Quan CapitalRoche Venture Fund
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoAlexandriaBiotechnology Value FundCasdin Capital+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.